Log in to search using one of your social media accounts:

Cilostazol Cilostazol RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

This page shows you the latest news items in this category.

Pletal (Cilostazol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 26, 2016 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [West-Ward Pharmaceuticals Corp.]
Updated Date: Jul 6, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - July 6, 2016 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [Avera McKennan Hospital]
Updated Date: Mar 1, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - March 1, 2016 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [Avera McKennan Hospital]
Updated Date: Dec 18, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - December 18, 2015 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [Eon Labs, Inc.]
Updated Date: Oct 28, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - October 28, 2015 Category: Drugs & Pharmacology Source Type: news

Cilostazol Bridges Surgical DES Patients Without DAPTCilostazol Bridges Surgical DES Patients Without DAPT
Based on long-term follow-up in an observational study, the PDE-3 inhibitor was called an "ingenious bridge" for patients taken off standard dual-antiplatelet therapy during surgery. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 12, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

CILOSTAZOL Tablet [Golden State Medical Supply, Inc.]
Updated Date: May 5, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - May 5, 2015 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [Golden State Medical Supply, Inc.]
Updated Date: Mar 30, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 30, 2015 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [Apotex Corp.]
Updated Date: Mar 13, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 13, 2015 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [Roxane Laboratories, Inc]
Updated Date: Mar 5, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 5, 2015 Category: Drugs & Pharmacology Source Type: news

Pletal (Cilostazol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 13, 2015 Category: Drugs & Pharmacology Source Type: news

PLETAL (Cilostazol) Tablet [Otsuka America Pharmaceutical, Inc.]
Updated Date: Feb 9, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 9, 2015 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [Carilion Materials Management]
Updated Date: Aug 15, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 15, 2014 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [American Health Packaging]
Updated Date: Aug 11, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 11, 2014 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [Preferred Pharmaceuticals, Inc.]
Updated Date: Jul 31, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - July 31, 2014 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [Teva Pharmaceuticals USA Inc]
Updated Date: Jul 24, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - July 24, 2014 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [BIOKEY INC.]
Updated Date: Apr 1, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - April 1, 2014 Category: Drugs & Pharmacology Source Type: news

Two Antiplatelet Add-on Regimens About Equal (CME/CE)
(MedPage Today) -- Adding cilostazol (Pletal) to standard dual antiplatelet therapy performed as well as doubling the dose of clopidogrel (Plavix) after implantation of a drug-eluting stent, the HOST-ASSURE study showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 17, 2013 Category: Cardiology Source Type: news

EMA recommends restricting cilostazol use for PAD
The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual anticoagulants. (Source: theHeart.org)
Source: theHeart.org - March 22, 2013 Category: Cardiology Source Type: news

EMA Recommends Restricting Cilostazol Use for PADEMA Recommends Restricting Cilostazol Use for PAD
The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual anticoagulants News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 22, 2013 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

EU medicines agency to restrict use of Otsuka drug
LONDON (Reuters) - The European Medicines Agency said on Friday it was recommending restricting the use of medicines containing cilostazol, sold by Otsuka under the brand name Pletal, following concerns over side effects. (Source: Reuters: Health)
Source: Reuters: Health - March 22, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

European Medicines Agency recommends restricting use of cilostazol-containing medicines
Source: EMA Area: News Following a review of the current evidence, the European Medicines Agency's (EMA) Committee on Medicinal Products for Human Use (CHMP) has recommended that the use of cilostazol in the treatment of intermittent claudication should be restricted with a range of new measures aimed at targeting a patient population in which there are clinical benefits, and at the same time minimising important risks.   The Spanish Agency for Medicines and Health Products (AEMPS) asked the CHMP to carry out a review of cilostazol following a number of reports of serious suspected adverse effects, in particular ...
Source: NeLM - Cardiovascular Medicine - March 22, 2013 Category: Cardiology Source Type: news

Cilostazol reduces revascularization rates after percutaneous coronary intervention
NEW YORK (Reuters Health) - Adding cilostazol to dual antiplatelet therapy cuts revascularization rates after percutaneous coronary intervention (PCI), but has no impact on heart attacks or deaths, according to a new meta-analysis. (Source: Modern Medicine)
Source: Modern Medicine - April 6, 2012 Category: Journals (General) Source Type: news

ACC: Three Equals Two in Antiplatelet Regimen (CME/CE)
CHICAGO (MedPage Today) -- Adding cilostazol (Pletal) to dual antiplatelet therapy after stenting appears equivalent to doubling the dose of clopidogrel (Plavix), Korean researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 26, 2012 Category: Cardiology Source Type: news

cilostazol, Pletal
Title: cilostazol, PletalCategory: MedicationsCreated: 4/17/1999 8:43:00 PMLast Editorial Review: 3/22/2012 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 22, 2012 Category: Cardiology Source Type: news

Platelet Reactivity in CKD - Cilostazol vs ClopidogrelPlatelet Reactivity in CKD - Cilostazol vs Clopidogrel
Learn more about functional impact of cilostazol on platelets in CKD patients undergoing hemodialysis. American Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 5, 2012 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Systematic review and economic evaluation: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treatment of intermittent claudication
Source: Health Technology Assessment (HTA) Area: Evidence > Drug Specific Reviews This systematic review conducted by researchers with the NHS Health Technology Assessment (HTA) programme examined the clinical- and cost-effectiveness of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate, compared with no vasoactive drugs, for intermittent claudication in people with peripheral arterial disease whose symptoms continue despite a period of conventional management.   A search for literature carried out between April to June 2010 identified 26 RCTs that met the inclusion criteria for the cli...
Source: NeLM - Drug Specific Reviews - December 15, 2011 Category: Drugs & Pharmacology Source Type: news

Cilostazol improves clopidogrel platelet inhibitory effect in CKD patients
Adding cilostazol to antiplatelet therapy improves platelet inhibition in patients with chronic kidney disease undergoing hemodialysis, research shows. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - December 7, 2011 Category: Cardiology Source Type: news

Cilostazol improves clopidogrel platelet inhibitory effect in CKD patients
Adding cilostazol to antiplatelet therapy improves platelet inhibition in patients with chronic kidney disease undergoing hemodialysis, research shows. (Source: MedWire News - Thrombosis)
Source: MedWire News - Thrombosis - December 7, 2011 Category: Internal Medicine Source Type: news

Antiplatelet therapies comparable in intracranial stenosis
NEW YORK (Reuters Health) - Aspirin in combination with cilostazol or clopidogrel appears to have a similar inhibitory effect on progression of symptomatic intracranial atherosclerotic stenosis (ICAS), Korean researchers report. However, cilostazol may have advantages. (Source: Modern Medicine)
Source: Modern Medicine - August 15, 2011 Category: Journals (General) Source Type: news

NICE Bites - June 2011: Multiple TA; Peripheral arterial disease & Common mental health disorders
Source: North West Medicines Information Centre Area: Health In Focus NICE Bites is a monthly bulletin which summarises key prescribing points from NICE guidance. This edition includes two topics; Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease and Common mental health disorders. (Source: NeLM - Health In Focus)
Source: NeLM - Health In Focus - June 22, 2011 Category: UK Health Source Type: news

NICE issues guidance on cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication
Source: NICE Area: Evidence> Guidelines The National Institute for Health and Clinical Excellence (NICE) has issued guidance on the use of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in patients with peripheral arterial disease. The following recommendations have been made (taken directly from source):     . Naftidrofuryl oxalate is recommended as an option for the treatment of intermittent claudication in people with peripheral arterial disease for whom vasodilator therapy is considered appropriate after taking into account ...
Source: NeLM - Guidelines - May 25, 2011 Category: UK Health Source Type: news

European CHMP begins benefit-risk assessment of cilostazol-containing medicines,
Source: European Medicines Agency (EMA) Area: News The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has started a benefit-risk assessment of cilostazol-containing medicines, currently used to improve the maximal walking distance and maximal pain-free walking distances in patients with intermittent claudication. This review was triggered by Spain following the review of all safety reports during the first 18 months of marketing of these medicines. The safety review showed an increased risk of cardiovascular and haemorrhagic reactions. This increased risk has to be assessed in...
Source: NeLM - News - May 20, 2011 Category: Drugs & Pharmacology Source Type: news

NICE issues FAD on cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate for peripheral arterial disease
Source: NICE Area: News NICE has issued a Final Appraisal Determination (FAD) on cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate for peripheral arterial disease, which contains the following draft recommendations:   . Naftidrofuryl oxalate is recommended as an option for the treatment of intermittent claudication in people with peripheral arterial disease for whom vasodilator therapy is considered appropriate after taking into account other treatment options. Treatment with naftidrofuryl oxalate should be started with the least costly licensed preparation.   . Cilostaz...
Source: NeLM - News - April 14, 2011 Category: Drugs & Pharmacology Source Type: news

NICE issues preliminary recommendations (ACD) on cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate for peripheral arterial disease
Source: NICE Area: News NICE has been asked by the Department of Health to produce guidance on using cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (PAD) in the NHS in England and Wales.  An Appraisal Consultation Document (ACD) is now available, containing the following preliminary recommendations:   . Naftidrofuryl oxalate is recommended as an option for the treatment of intermittent claudication in people with peripheral arterial disease for whom vasodilator therapy is considered clini...
Source: NeLM - News - February 1, 2011 Category: Drugs & Pharmacology Source Type: news

JACC: Triple-antiplatelet therapy is no better than dual therapy
Despite a greater reduction of platelet reactivity by the addition of cilostazol to conventional dual-antiplatelet therapy, triple-antiplatelet therapy did not show superiority in reducing the composite of adverse cardiovascular outcomes after drug-eluting stent implantation, according to a study in the Jan. 18 Journal of the American College of Cardiology. (Source: Cardiovascular Business News)
Source: Cardiovascular Business News - January 17, 2011 Category: Cardiology Tags: Latest News Source Type: news

Cilostazol vs. Aspirin for Recurrent-Stroke Prevention
Is the phosphodiesterase inhibitor cilostazol as effective as aspirin at preventing recurrent stroke? Journal Watch (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 10, 2010 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Cilostazol Response Was High in Diabetes Patients
Major Finding: Adding cilostazol, 100 mg twice daily, to a standard regimen of dual-antiplatelet therapy with aspirin and clopidogrel cut platelet reactivity by an average of 23% in patients with diabetes, and by an average of 15% in patients without diabetes, statistically significant differences. (Source: Family Practice News)
Source: Family Practice News - November 1, 2010 Category: Primary Care Authors: MITCHEL L. ZOLER Tags: Metabolic Disorders Source Type: news

PLETAL (Cilostazol) Tablet [Otsuka America Pharmaceutical, Inc.]
Updated Date: Oct 28, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - October 28, 2010 Category: Drugs & Pharmacology Source Type: news

Cilostazol Is an Effective Antiplatelet Drug Following Stroke
(Source: AccessMedicine Updates)
Source: AccessMedicine Updates - October 10, 2010 Category: Internal Medicine Source Type: news

Similar Efficacy, Less Bleeding With Cilostazol vs Aspirin for Recurrent Stroke Prevention: CSPS 2 Published
Final results of the CSPS 2 trial, presented earlier this year, show a similar efficacy but fewer hemorrhagic events with cilostazol vs aspirin. Medscape Medical News (Source: Medscape Nurses Headlines)
Source: Medscape Nurses Headlines - September 29, 2010 Category: Nursing Tags: Neurology & Neurosurgery News Source Type: news

Cilostazol ‘might be superior’ to aspirin for secondary stroke prevention
Cilostazol is noninferior to aspirin for recurrent stroke prevention and is associated with less bleeding risk, say the CSPS 2 investigators. (Source: MedWire News - Stroke)
Source: MedWire News - Stroke - September 21, 2010 Category: Neurology Source Type: news

Cilostazol matches aspirin’s effectiveness in preventing secondary stroke
Read the full story on MD Consult: Cilostazol matches aspirin’s effectiveness in preventing secondary stroke (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - September 14, 2010 Category: Journals (General) Source Type: news

Cilostazol As Good As Aspirin for Stroke Prevention
The antiplatelet drug cilostazol is non-inferior, and possibly superior, to aspirin for secondary stroke prevention, and is associated with fewer hemorrhagic events, according to research from the second Cilostazol Stroke Prevention Study published online Sept. 11 in The Lancet Neurology. (Source: Modern Medicine)
Source: Modern Medicine - September 14, 2010 Category: Journals (General) Source Type: news

Cilostazol Seems to Outperform Aspirin in Preventing Secondary Stroke
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 13, 2010 Category: Primary Care Tags: Medical News Source Type: news

Cilostazol could cut repeat stroke rate
Using cilostazol, rather than aspirin, to prevent repeat stroke is associated with fewer bleeding events and may be more effective, a study has found. (Source: HealthcareRepublic Independent Nurse News)
Source: HealthcareRepublic Independent Nurse News - September 13, 2010 Category: Nursing Source Type: news

Cilostazol may have similar benefits as aspirin for secondary stroke prevention
This study aimed to determine whether it was non-inferior to aspirin as secondary prophylaxis in patients with non-cardioembolic ischaemic stroke. Participants were Japanese adults aged 20 to 79 who had suffered an ischaemic stroke within the previous 26 weeks. They were randomised to receive cilostazol 100mg bd or aspirin 81mg daily and followed up for the primary outcome of any stroke (cerebral infarction, cerebral haemorrhage, or subarachnoid haemorrhage). Serious bleeding (cerebral haemorrhage, subarachnoid haemorrhage, or haemorrhage requiring hospital admission) was a major safety outcome.   Over a period of...
Source: NeLM - News - September 13, 2010 Category: Drugs & Pharmacology Source Type: news

Second Strokes Less Common With Cilostazol (CME/CE)
(MedPage Today) -- The antiplatelet agent cilostazol (Pletal) appeared significantly more effective than aspirin for secondary prevention of strokes and was associated with fewer major bleeding events in a Japanese study. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 11, 2010 Category: Cardiology Source Type: news